Cost‐effectiveness of single‐dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in theUK

BJU International - Tập 112 Số 5 - Trang 638-646 - 2013
Anna N. Walker1, Scott Doyle2, John Posnett1, M Hunjan2
1Heron Evidence Development Ltd., Luton, UK
2GlaxoSmithKline Health Outcomes UK Uxbridge UK

Tóm tắt

What's known on the subject? and What does the study add?UKclinical guidelines for treating male patients with moderate to severeLUTSassociated withBPHrecommend treatment with an alpha‐blocker (such as tamsulosin) in cases where conservative management options have not been successful or are not appropriate. An alpha‐blocker plus 5‐alpha‐reductase inhibitor (such as dutasteride) is recommended for those patients with moderate to severe symptoms and prostate volume >30 mL.The present study evaluates the cost‐effectiveness of a new, single‐dose combination of tamsulosin and dutasteride (Combodart®) from the perspective of theUK NationalHealthService. The results show that the combination therapy has a high probability of being cost‐effective compared with either monotherapy, and compared with the two therapies taken separately. The probability of the combination therapy being cost‐effective at an incremental cost‐effectiveness ratio threshold in the range £25 000–£30 000 per quality‐adjusted life year is 78–88%.ObjectiveTo estimate the long‐term cost‐effectiveness of single‐dose dutasteride/tamsulosin combination therapy as a first‐line treatment for benign prostatic hyperplasia (BPH) from the perspective of theUK NationalHealthService (NHS).MethodsAMarkov state transition model was developed to estimate healthcare costs and patient outcomes, measured by quality‐adjusted life years (QALYs), for patients aged ≥50 years with diagnosedBPHand moderate to severe symptoms.Costs and outcomes were estimated for two treatment comparators: oral, daily, single‐dose combination therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg), and oral daily tamsulosin (0.4 mg) over a period up to 25 years.The efficacy of comparators was taken from results of theCombination ofAvodart andTamsulosin (CombAT) trial.ResultsCumulative discounted costs per patient were higher with combination therapy than with tamsulosin, butQALYswere also higher.After 25 years, the incremental cost‐effectiveness ratio for combination therapy was £12 219, well within the threshold range (£20 000–£30 000 perQALY) typically applied in theNHS.Probabilistic sensitivity analysis showed that the probability of combination therapy being cost‐effective given the threshold range is between 78% and 88%.ConclusionSingle‐dose combination dutasteride/tamsulosin therapy has a high probability of being cost‐effective in comparison to tamsulosin monotherapy in theUK‘sNHS.

Từ khóa


Tài liệu tham khảo

Trueman P, 1999, Prevalence of lower urinary tract symptoms and self reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community based survey of men in the UK, BJU Int, 49, 410, 10.1046/j.1464-410x.1999.00966.x

10.1016/S0302-2838(02)00354-8

Garraway WM, 1993, Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle‐aged and elderly men, Br J Gen Pract, 43, 318

10.1111/j.1742-1241.2007.01635.x

10.1016/S0090-4295(97)00077-0

Barone JG, 1994, Aetiology of acute urinary retention following benign ano‐rectal surgery, Ann Surg, 60, 210

10.1016/S1056-8727(96)00107-9

10.1016/S0003-9993(95)80128-6

Drug Patent Watch Website. Available at:http://www.drugpatentwatch.com/ultimate/preview/ingredient/index.php?query=TAMSULOSIN%20HYDROCHLORIDE. Accessed May 2012

Chapple C, 2010, The Management of Lower Urinary Tract Symptoms in Men

10.1016/j.eururo.2009.09.035

10.1111/j.1742-1241.2010.02428.x

National Institute for Health and Clinical Excellence, 2009, The Guidelines Manual

10.18637/jss.v038.i08

Briggs A, 2006, Decision Modelling for Health Economic Evaluation, 10.1093/oso/9780198526629.001.0001

10.1136/bmj.318.7188.921

10.1016/j.eururo.2006.11.009

10.1046/j.1464-410x.1999.00359.x

Agency for Health Care Policy and Research, 1994, Benign Prostatic Hyperplasia: Diagnosis and Treatment

10.1159/000049784

NHS.NHS Clinical knowledge website. Available at:http://www.cks.nhs.uk. Accessed June 2010

Department of Health.NHS payment by results tariff 2010–11. Available at:http://data.gov.uk/dataset/payment‐by‐results‐2010‐11‐national‐tariff‐information. Accessed September 2011

Curtis L, 2010, Unit Costs of Health and Social Care 2010

Joint Formulary Committee, 2010, British National Formulary (2010), Number 60

GlaxoSmithKline.ProState of the Nation Report: a call to action: delivering more effective care to BPH patients in the UK.2009

10.2165/00019053-199609050-00007

10.1016/S0090-4295(00)00828-1

10.3310/hta12350

Takayama T, 2012, Pharmacoeconomic evaluation of combination therapy with dutasteride and α1 blocker for treatment of benign prostatic hyperplasia in Japan, Hinyokika Kiyo, 58, 61

10.1111/j.1464-410X.2011.10511.x

Antonanzas F, 2011, Cost‐effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperplasia in Spain, Actas Urol Esp, 3592, 65, 10.1016/j.acuro.2010.11.008

10.1136/bmj.b1288

10.1111/j.1528-1167.2007.01279.x

10.1097/01.ju.0000165569.48372.4c

Thông tin
Thông tin xuất bản

BJU International

Tập 112 Số 5

638-646

Thông tin tác giả